The market for treatment of androgenetic alopecia (hair loss) is substantial. In the US alone 60 million men and 35 million women are suffering from hair loss whereas only 2,7 million men and 2 million women are being treated. The current market for medical treatments is valued at more than 8 billion USD globally (https://www.grandviewresearch.com/industry-analysis/alopecia-market).
Finasteride and minoxidil are the dominant medical treatments, which have limited effect and only up to 40% of patients respond to treatment. In the last 30 years no new medical treatment has been introduced and the pipeline is based mainly on reformulation of these existing therapies.
Chairman of the Board
Member of the Board